End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27,550 KRW | +1.66% | +0.73% | +6.99% |
24/04 | US solar panel makers seek new tariffs to protect domestic factories | RE |
17/04 | US plans to restore tariffs on dominant solar technology, sources say | RE |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Its low valuation, with P/E ratio at 5.68 and 3.02 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company shows low valuation levels, with an enterprise value at 36.34 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.99% | 1.49B | B | ||
+12.85% | 77.41B | B- | ||
+8.36% | 50.67B | B+ | ||
+2.82% | 48.12B | B | ||
+14.75% | 43.61B | B+ | ||
+12.52% | 41.74B | B+ | ||
+5.98% | 30.76B | B | ||
-2.46% | 29.21B | B- | ||
-12.42% | 26.1B | A- | ||
+11.26% | 23.07B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A000880 Stock
- Ratings Hanwha Corporation